Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and
etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what
extent they are associated with an increased risk of infectious adverse events. Areas
covered: We conducted a systematic review and meta-analysis of published randomized
studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse …

Introduction: Malignancies have been reported in patients with rheumatoid arthritis, psoriatic
arthritis and ankylosing spondylitis, treated with anti-tumour necrosis factor (anti-TNF)
agents. Areas covered: We conducted a systematic review of randomized controlled trials
(RCTs) to determine the effect of anti-TNF agents on the occurrence of cancer (any type).
Literature databases were searched up to May 2014 to identify relevant studies that
evaluated adalimumab, certolizumab, etanercept, golimumab, or infliximab, compared with …